Myelodysplastic neoplasms / syndromes

Diagnosis integrates persistent cytopenias, marrow morphology, blast percentage, cytogenetics and molecular testing. Nutritional deficiency, medicines, infection, autoimmune disease and other marrow disorders can resemble MDS and need appropriate exclusion. Clonal hematopoiesis or CCUS is not automatically MDS.

WHO uses myelodysplastic neoplasms, while syndrome remains common in clinical and regulatory wording. Categories may be defined by del(5q), SF3B1 or biallelic TP53 alterations, or by morphology and blast level. The ICC includes an MDS/AML category for selected cases with 10–19% blasts; genetic AML-defining exceptions and framework differences require specialist interpretation.

IPSS-R uses blood counts, marrow blasts and cytogenetics. IPSS-M adds molecular information and can move a patient into a different risk group. Ask which score was calculated, whether the gene panel was adequate and whether the result reflects the current disease rather than an old marrow sample.

Risk helps estimate disease course and plan transplant timing; it is not an individual countdown. Severe cytopenias, infections, bleeding, transfusion burden, fitness and patient goals can change management even within the same score category.

Some patients can be monitored with supportive care. When anemia needs treatment, serum erythropoietin, transfusion burden, del(5q), SF3B1/ring sideroblasts and prior therapy help select an approach. ESAs remain useful in selected patients; lenalidomide has a specific role in del(5q)-associated transfusion-dependent disease.

Luspatercept has a US indication for anemia in ESA-naive adults with very-low to intermediate-risk MDS who may need regular transfusions. COMMANDS compared it with epoetin alfa in a defined transfusion-dependent population. Eligibility differs between first-line and post-ESA settings; the drug should not be described as restricted to all and only SF3B1-mutated cases.

The US imetelstat indication is for adults with low- to intermediate-1-risk MDS and transfusion-dependent anemia requiring at least four red-cell units over eight weeks, after ESA nonresponse, lost response or ineligibility. These are specific label criteria, not a general treatment for every low blood count.

The practical goal is a meaningful period without transfusions or a lower burden, with better daily function. Blood counts and liver tests need monitoring; neutropenia and thrombocytopenia can limit treatment. Transfusion independence is valuable but should not be presented as eradication of MDS.

Higher-risk treatment aims to control the abnormal clone, delay progression and preserve a route to transplant where appropriate. Azacitidine, decitabine or an approved oral decitabine/cedazuridine formulation may be considered. Oral and injectable products are not freely interchangeable, and different oral azacitidine products should not be substituted.

Response often requires serial cycles and marrow review, while early cytopenias need careful management. Adding venetoclax is not automatically a proven better standard: the phase III VERONA trial did not improve its primary overall-survival endpoint. Selected bridging or trial use needs a clear rationale rather than extrapolation from AML.

Discuss transplant early for eligible higher-risk patients and selected lower-risk patients with adverse genetics or severe disease consequences. Assessment includes comorbidities, frailty, donor availability, disease control and the expected balance of relapse against nonrelapse mortality and graft-versus-host disease.

Possible inherited predisposition affects counseling, donor selection and sometimes conditioning. A mutation found on a tumor panel is not automatically inherited, but suspicious personal or family history can justify germline assessment before selecting a related donor.

When counts worsen or hypomethylating treatment loses effect, reassess marrow, blasts and molecular findings. This can reveal progression, AML transformation or a treatment-related problem. Trial options and transplant feasibility should be reviewed before repeated ineffective cycles consume time.

Ivosidenib has a US indication for adults with relapsed or refractory MDS harboring a susceptible IDH1 mutation confirmed by an approved test. This is a selected molecular subgroup, not all HMA-refractory disease. Differentiation syndrome, QT prolongation and drug interactions require specialist monitoring.

For other patients, no single salvage regimen reliably solves post-HMA disease. Investigational combinations and immune or cellular strategies should be presented with their trial phase and entry conditions, not as established curative alternatives.

Transfusion thresholds are individualized to symptoms and comorbidities. Infection prevention, prompt fever assessment, bleeding precautions and selected iron-overload management remain important during both observation and active therapy. Fever during neutropenia, significant bleeding or new breathlessness needs urgent assessment.

Bring marrow reports and slides, cytogenetics and mutation results, score calculations, blood-count and transfusion records, ESA exposure, treatment dates and responses. Ask whether the immediate goal is less transfusion, disease modification or transplant preparation, and what finding would trigger a change.